Search Videos and More
Video
Blood Cancer: Higher rates of precursor in high-risk individuals
Dr. Irene Ghobrial and Dr. Habib El-Khoury shared the first results from the Promise study, which screens individuals at high risk for multiple myeloma.
News
Drug Combination Found to Keep Chronic Lymphocytic Leukemia in Young Patients in Remission for Several Years
A new study by Dana-Farber Cancer Institute researchers suggests that a 2.5-year regimen involving ibrutinib and chemoimmunotherapy can provide deep, and lasting remissions for patients with chronic lymphocytic leukemia (CLL).
News
Molecular Analysis Advances Risk Profiling and Assessment of Immunotherapy Response in Smoldering Myeloma
Molecular and genetic research by scientists at Dana-Farber Cancer Institute has advanced the categorization of different risk groups in patients with smoldering myeloma, a premalignant condition that can – but doesn’t always – progress to the blood cancer, multiple myeloma.
News
American Society of Hematology (ASH) Annual Meeting
As leaders in blood and blood cancer research, physicians and scientists from Dana-Farber Cancer Institute shared advances and insights at the 63rd Annual Meeting of the American Society of Hematology (ASH) on December 11–14, 2021 in Atlanta, Georgia
News
New Study Reveals Elevated Rates of Blood Cancer Precursor Condition in Groups at High Risk for Multiple Myeloma
The first results from the largest screening study yet conducted in the United States of individuals at above-average risk for the blood cancer multiple myeloma have revealed higher rates of a myeloma precursor condition in older adults who are Black or who have a close family member with a current or past blood cancer.
Document
ASH 2021 Featured Oral Presentations
The Annual Meeting of the American Society of Hematology (ASH) will take place December 11-14th. To keep-up with latest advances, the live schedule of oral presentations by Dana-Farber faculty is attached for your convenience.
News
Discovery May Lead to Expanded Donor Pool for Stem Cell Transplants for Patients with Cancer
Researchers find that in many cases people with a condition known as clonal hematopoiesis can safely serve as stem cell transplant donors.
News
Finding New Targets for Acute Myeloid Leukemia in Children
Looking for genes AML needs for everyday survival turned up two strong ‘hits’ to pursue for therapeutic development.
News
Study Results Support Stem Cell Transplantation for Older Patients with Myelodysplastic Syndromes
Although stem cell transplantation is the only current therapy with the potential to cure myelodysplastic syndromes (MDS), it is rarely used as an initial treatment for older patients because it hasn’t been proven superior to other therapies. New research by Dana-Farber Cancer Institute investigators stands to overturn that practice.
Document
Mantle Cell Lymphoma Clinical Trial
Targeted combination therapy for mantle cell lymphoma with minimal residual disease assessment.
Video
Clinical Trial Spotlight: Venetoclax plus Chemotherapy for Older Patients with Acute Lymphoblastic Leukemia (ALL)
Dr. Marlise Luskin, a specialist in the Adult Leukemia Program at Dana-Farber Cancer Institute, explains an innovative trial that combines the BCL2 inhibitor, venetoclax with chemotherapy for older patients with ALL.
Video
Stem Cell Transplant Beneficial for Older Patients with Myelodysplastic Syndrome
New research shows stem cell transplant represents the best therapeutic approach for older individuals with myelodysplastic syndrome. Dana-Farber Cancer Institute's Corey Cutler, MD, MPH, FRCPC explains more.